What is PathAdvantage?
PathAdvantage operates as a pathologist-owned laboratory, delivering a comprehensive suite of anatomic and clinical pathology services. The company distinguishes itself through advanced diagnostic tests, including the MatrixBrush Endometrial Sampler and specialized vaginal health diagnostics. PathAdvantage is dedicated to providing superior service to healthcare providers, emphasizing rapid turnaround times and personalized support. Its proprietary resources, such as The Bug Book, are invaluable tools for medical professionals in the diagnosis and treatment of infectious agents, ultimately aiming to elevate patient care through cutting-edge testing and an unwavering commitment to quality.
How much funding has PathAdvantage raised?
PathAdvantage has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in PathAdvantage
PPP
Public-Private Partnership
What's next for PathAdvantage?
The recent major strategic investment provides PathAdvantage with substantial capital to further its mission of enhancing patient care through advanced pathology services. This infusion of financing is expected to fuel expansion into new markets, accelerate the development of proprietary diagnostic tools, and bolster its operational capacity to meet growing demand. The company's focus on innovation, exemplified by resources like The Bug Book, positions it for continued leadership in the competitive diagnostic testing landscape. Future growth will likely involve strategic partnerships and the integration of new technologies to broaden its service offerings and solidify its market presence.
See full PathAdvantage company page
